Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06716554 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
A NA study of Menopause and Mood, sponsored by SF Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT06716554: Recruiting NA study of Menopause and Mood, sponsored by SF Research Institute.
NCT06716554 is a NA study of Menopause and Mood that is actively recruiting participants, run by SF Research Institute. The registered enrollment target is 51 participants, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06716554, a NA study of Menopause and Mood, is actively recruiting participants, sponsored by SF Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of Shatavari for the treatment of Menopausal symptoms in Women. Participants will be randomized to either one of the three treatment arms.Participants will then be asked to either take one capsule containing Shatavari or Shatavari + Ashwagandha or Placebo orally once daily in the morning after breakfast with a glass of water for 8 weeks. All the subjects will be asked to continue their routine diet and physical activities during the whole study period. The primary objective is to compare the efficacy of shatavari for treatment of menopausal symptoms in women. The secondary objective is to compare the safety of shatavari for treatment of menopausal symptoms in women.
Primary Outcome
The scale consisted of 11 items, ranging from no symptoms to very severe symptoms. The total score of the MRS ranges from 0 (asymptomatic) to 44 (highest degree of complaints). The minimal/maximal scores vary between the three dimensions, depending on the number of complaints allocated to the respective dimension of symptoms.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Shatavari extract
- DIETARY_SUPPLEMENT Shatavari + Ashwagandha extract
Study Locations (1)
California
- SF Research Institute, Inc. - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2024-10-26 |
| Est. Completion | 2025-01-20 |
| Phase | NA |
What NCT06716554 shows while recruiting
NCT06716554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Menopause appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06716554 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06716554 about?
NCT06716554 is a clinical study titled "Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study". This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of Shatavari for the treatment of Menopausal symptoms in Women. Participants will be randomized to either one of the three treatment arms.Participant...
What is the current status of trial NCT06716554?
This trial is currently recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2024-10-26. Estimated completion is 2025-01-20.
What conditions does trial NCT06716554 study?
This clinical trial studies the following conditions: Menopause, Mood, Hot Flashes.
What interventions are being tested in trial NCT06716554?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Shatavari extract (DIETARY_SUPPLEMENT), Shatavari + Ashwagandha extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06716554?
This trial is sponsored by SF Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06716554 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06716554's enrollment target sits among peer trials
51 34th of 54 higher than 21 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hot Flashes and Neurovascular Function in Women
RECRUITING · NA
-
Improving Sympathetic Activity, Hot Flashes, and Sleep in Midlife Women Using Inspiratory Muscle Strength Training
RECRUITING · NA
-
Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females
RECRUITING · NA
-
Depression, Aging, Stress and Heart Health Study
RECRUITING · NA
-
Choline Dose Ranging in Postmenopausal Women
RECRUITING · NA
-
Following Lipectomy to Understand Adipose Tissue Re-accumulation
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI